Vital Signs: Prescription Opioid Pain Reliever Use During Pregnancy - 34 U.S. Jurisdictions, 2019.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
17 Jul 2020
Historique:
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 18 7 2020
Statut: epublish

Résumé

Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%-22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited. CDC analyzed 2019 data from the Pregnancy Risk Assessment Monitoring System (PRAMS) survey in 32 jurisdictions and maternal and infant health surveys in two additional jurisdictions not participating in PRAMS to estimate self-reported prescription opioid pain reliever (prescription opioid) use during pregnancy overall and by maternal characteristics among women with a recent live birth. This study describes source of prescription opioids, reasons for use, want or need to cut down or stop use, and receipt of health care provider counseling on how use during pregnancy can affect an infant. An estimated 6.6% of respondents reported prescription opioid use during pregnancy. Among these women, 21.2% reported misuse (a source other than a health care provider or a reason for use other than pain), 27.1% indicated wanting or needing to cut down or stop using, and 68.1% received counseling from a provider on how prescription opioid use during pregnancy could affect an infant. Among respondents reporting opioid use during pregnancy, most indicated receiving prescription opioids from a health care provider and using for pain reasons; however, answers from one in five women indicated misuse. Improved screening for opioid misuse and treatment of opioid use disorder in pregnant patients might prevent adverse outcomes. Implementation of public health strategies (e.g., improving state prescription drug monitoring program use and enhancing provider training) can support delivery of evidence-based care for pregnant women.

Sections du résumé

BACKGROUND BACKGROUND
Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%-22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.
METHODS METHODS
CDC analyzed 2019 data from the Pregnancy Risk Assessment Monitoring System (PRAMS) survey in 32 jurisdictions and maternal and infant health surveys in two additional jurisdictions not participating in PRAMS to estimate self-reported prescription opioid pain reliever (prescription opioid) use during pregnancy overall and by maternal characteristics among women with a recent live birth. This study describes source of prescription opioids, reasons for use, want or need to cut down or stop use, and receipt of health care provider counseling on how use during pregnancy can affect an infant.
RESULTS RESULTS
An estimated 6.6% of respondents reported prescription opioid use during pregnancy. Among these women, 21.2% reported misuse (a source other than a health care provider or a reason for use other than pain), 27.1% indicated wanting or needing to cut down or stop using, and 68.1% received counseling from a provider on how prescription opioid use during pregnancy could affect an infant.
CONCLUSIONS AND IMPLICATIONS FOR PUBLIC HEALTH PRACTICE UNASSIGNED
Among respondents reporting opioid use during pregnancy, most indicated receiving prescription opioids from a health care provider and using for pain reasons; however, answers from one in five women indicated misuse. Improved screening for opioid misuse and treatment of opioid use disorder in pregnant patients might prevent adverse outcomes. Implementation of public health strategies (e.g., improving state prescription drug monitoring program use and enhancing provider training) can support delivery of evidence-based care for pregnant women.

Identifiants

pubmed: 32673301
doi: 10.15585/mmwr.mm6928a1
pmc: PMC7366850
doi:

Substances chimiques

Analgesics, Opioid 0
Prescription Drugs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

897-903

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

Am J Public Health. 2018 Oct;108(10):1305-1313
pubmed: 30138070
JAMA. 2016 Apr 19;315(15):1624-45
pubmed: 26977696
Obstet Gynecol. 2017 Aug;130(2):e81-e94
pubmed: 28742676
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
Obstet Gynecol. 2014 May;123(5):997-1002
pubmed: 24785852
J Pregnancy. 2014;2014:906723
pubmed: 25254116
Obstet Gynecol. 2018 Aug;132(2):466-474
pubmed: 29995730
Pediatrics. 2015 May;135(5):842-50
pubmed: 25869370
Obstet Gynecol. 2019 Aug;134(2):365-375
pubmed: 31306323
MMWR Morb Mortal Wkly Rep. 2019 Sep 13;68(36):777-783
pubmed: 31513558
Womens Health Issues. 2017 May - Jun;27(3):308-315
pubmed: 28408072
Anesthesiology. 2014 May;120(5):1216-24
pubmed: 24525628
JAMA. 2020 Jun 9;323(22):2301-2309
pubmed: 32515821
Ann Intern Med. 2017 Sep 5;167(5):293-301
pubmed: 28761945

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH